Hologic (HOLX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
29 Jan, 2026Executive summary
Special stockholder meeting set for February 5, 2026, to vote on the proposed acquisition by Blackstone and TPG, with related proxy materials distributed.
Q1 fiscal 2026 revenue reached $1,047.8 million, up 2.5% year-over-year; organic revenue excluding COVID-19 and certain businesses rose 2.9%.
GAAP diluted EPS was $0.79, down 9.2%, while non-GAAP diluted EPS increased 1.0% to $1.04; cash flow from operations grew 21.4% to $229.9 million.
No financial guidance for fiscal 2026 due to the pending acquisition; no earnings call scheduled.
Voting matters and shareholder proposals
Stockholders will vote on the adoption of the merger agreement with Blackstone and TPG and related matters at a special meeting.
Board of directors and corporate governance
Information on directors, executive officers, and their interests in the merger is detailed in the proxy statement and recent SEC filings.
Latest events from Hologic
- Q3 revenue and EPS exceeded guidance, led by strong core segment growth and margin gains.HOLX
Q3 20242 Feb 2026 - Strong growth, innovation, and global expansion drive robust financial and operational performance.HOLX
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - Revenue up 2.5% to $1.05B; merger with Blackstone/TPG on track for H1 2026 close.HOLX
Q1 202629 Jan 2026 - Merger, litigation, and product recall updates shape shareholder decisions and future outlook.HOLX
Proxy Filing26 Jan 2026 - International growth, recurring revenue, and innovation drive strong performance and future outlook.HOLX
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q4 revenue up 4.5% with strong segment growth and positive FY2025 outlook.HOLX
Q4 202417 Jan 2026 - Shareholders to receive $76 per share plus CVR in Blackstone/TPG acquisition, with key risks disclosed.HOLX
Proxy Filing12 Jan 2026 - Strong Q4, 2025 growth guided at 4%, with innovation and M&A fueling future expansion.HOLX
7th Annual Evercore ISI HealthCONx Conference12 Jan 2026 - Envision gantry launch, robust molecular growth, and margin improvement drive 2025 outlook.HOLX
Citi's 2024 Global Healthcare Conference12 Jan 2026